![No Image](https://cambridgebreastclinic.com/wp-content/themes/mh-magazine-lite/images/placeholder-medium.png)
AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn’s Disease in the U.S.
/PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI®…